18.39
1.54%
-0.325
Arrowhead Pharmaceuticals Inc stock is traded at $18.39, with a volume of 90,256.
It is down -1.54% in the last 24 hours and down -10.10% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
See More
Previous Close:
$18.71
Open:
$18.75
24h Volume:
90,256
Relative Volume:
0.09
Market Cap:
$2.32B
Revenue:
$181.74M
Net Income/Loss:
$-296.81M
P/E Ratio:
-10.75
EPS:
-1.71
Net Cash Flow:
$-402.70M
1W Performance:
-13.96%
1M Performance:
-10.10%
6M Performance:
-26.37%
1Y Performance:
-35.07%
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ARWR | 18.36 | 2.32B | 181.74M | -296.81M | -402.70M | -1.71 |
VRTX | 447.62 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.31 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 590.40 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.88 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.29 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-23 | Initiated | BofA Securities | Buy |
Sep-19-23 | Initiated | Citigroup | Neutral |
Jul-21-23 | Initiated | TD Cowen | Outperform |
May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
Apr-26-23 | Initiated | SMBC Nikko | Outperform |
Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-19-22 | Resumed | Goldman | Buy |
Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
Jun-04-21 | Resumed | Robert W. Baird | Neutral |
Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Dec-16-20 | Initiated | UBS | Buy |
Nov-19-20 | Initiated | Citigroup | Buy |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Mar-17-20 | Initiated | Goldman | Neutral |
Jan-21-20 | Initiated | SVB Leerink | Underperform |
Dec-13-19 | Initiated | Oppenheimer | Perform |
Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
Nov-27-19 | Reiterated | B. Riley FBR | Buy |
Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
Oct-03-19 | Initiated | Robert W. Baird | Outperform |
Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Principal Financial Group Inc. Has $5.64 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics - Barchart
Familial Chylomicronemia Syndrome Market Expected - openPR
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Tuesday - MarketBeat
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - BioSpace
Arrowhead seeks FDA nod for rare disease drug - Investing.com
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 6.3%Here's What Happened - MarketBeat
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Privium Fund Management B.V. Has $6.46 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Leerink Partnrs Has Positive Outlook of ARWR FY2024 Earnings - MarketBeat
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - BioSpace
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace
abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Launches FCS Awareness Campaign - Baystreet.ca
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaig - GuruFocus.com
In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St
International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
(ARWR) Long Term Investment Analysis - Stock Traders Daily
Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat
(ARWR) Trading Signals - Stock Traders Daily
Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat
State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - GlobeNewswire
Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace
HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com
Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highl - GuruFocus.com
Arrowhead Pharmaceuticals Plans $250M Manufacturing Plant in Wisconsin - Pasadena Now
How to Take Advantage of moves in (ARWR) - Stock Traders Daily
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Overweight Rating at Piper Sandler - MarketBeat
Goldman Sachs holds Neutral rating on Arrowhead stock By Investing.com - Investing.com Canada
Arrowhead Pharma maintains Buy rating from TD Cowen after R&D day insights - Investing.com Canada
Arrowhead Pharma retains Overweight rating from Piper Sandler By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year LowShould You Sell? - MarketBeat
ARWR stock touches 52-week low at $18.14 amid market challenges - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Millennium Management LLC - MarketBeat
Bank of Montreal Can Buys 30,866 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment? - Simply Wall St
Arrowhead: A First Approval LikelyJury Still Out On Investment Opportunity (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low at $18.61 - MarketBeat
Severe Hypertriglyceridemia Market Growth to Accelerate - openPR
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrowhead Pharmaceuticals Inc Stock (ARWR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Vakiener Victoria | Director |
May 02 '24 |
Sale |
23.31 |
1,799 |
41,935 |
30,205 |
Hamilton James C | Chief Discovery/Trans Medicine |
Apr 01 '24 |
Sale |
28.03 |
6,000 |
168,180 |
204,851 |
Lu Hongbo | Director |
Mar 19 '24 |
Buy |
28.00 |
1,000 |
28,000 |
32,680 |
Lu Hongbo | Director |
Mar 20 '24 |
Buy |
27.50 |
1,000 |
27,500 |
33,680 |
Lu Hongbo | Director |
Mar 18 '24 |
Buy |
27.49 |
1,000 |
27,490 |
31,680 |
Myszkowski Kenneth Allen | Chief Financial Officer |
Mar 06 '24 |
Sale |
35.19 |
40,000 |
1,407,600 |
400,600 |
Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Option Exercise |
14.54 |
57,499 |
836,035 |
3,772,547 |
Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Sale |
32.35 |
57,499 |
1,860,019 |
3,715,048 |
Hamilton James C | Chief Discovery/Trans Medicine |
Jan 12 '24 |
Sale |
36.89 |
7,940 |
292,904 |
210,851 |
GIVEN DOUGLAS B | Director |
Jan 11 '24 |
Sale |
38.06 |
2,911 |
110,788 |
129,711 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):